Kolóna na leukocytoferezu Cellsorba LX Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

kolóna na leukocytoferezu cellsorba lx

asahi kasei kuraray medical 1-105 kanda jinbocho chiyoda-ku,tokyo japonsko -

Aldurazyme Európska únia - slovenčina - EMA (European Medicines Agency)

aldurazyme

sanofi b.v. - laronidáza - mucopolysacharidóza i - iné alimentárny trakt a metabolizmus výrobky, - aldurazyme je určený pre dlhodobé enzým substitučná terapia u pacientov s potvrdená diagnóza mucopolysaccharidosis i (mps i, alfa-l-iduronidase nedostatok) na liečbu nonneurological prejavy ochorenia.

Dimethyl fumarate Polpharma Európska únia - slovenčina - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarát - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Neuraxpharm Európska únia - slovenčina - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarát - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Teva Európska únia - slovenčina - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetylfumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord Európska únia - slovenčina - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimetylfumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).